Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory of Diagnosis and Therapy of Lysosomal Disorders, |
RCV000677610 | SCV000803127 | uncertain significance | Mucopolysaccharidosis type 6 | 2018-01-01 | criteria provided, single submitter | curation | Absent from GnomAD (PM2) |
Labcorp Genetics |
RCV000677610 | SCV003525729 | pathogenic | Mucopolysaccharidosis type 6 | 2022-07-18 | criteria provided, single submitter | clinical testing | This missense change has been observed in individual(s) with mucolipidosis VI (PMID: 17458871). For these reasons, this variant has been classified as Pathogenic. This variant disrupts the p.Pro313 amino acid residue in ARSB. Other variant(s) that disrupt this residue have been determined to be pathogenic (PMID: 17458871, 17643332, 23557332, 27826022). This suggests that this residue is clinically significant, and that variants that disrupt this residue are likely to be disease-causing. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt ARSB protein function. ClinVar contains an entry for this variant (Variation ID: 559827). This variant is not present in population databases (gnomAD no frequency). This sequence change replaces proline, which is neutral and non-polar, with serine, which is neutral and polar, at codon 313 of the ARSB protein (p.Pro313Ser). |
Baylor Genetics | RCV000677610 | SCV005055579 | likely pathogenic | Mucopolysaccharidosis type 6 | 2024-01-28 | criteria provided, single submitter | clinical testing |